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Hematopoietic SCT in Europe: data and trends in 2012
with special consideration of pediatric transplantation
JR Passweg1, H Baldomero1, C Peters2, HB Gaspar3, S Cesaro4, P Dreger5, RF Duarte6, JHF Falkenburg7, D Farge-Bancel8, A Gennery9,
J Halter10, N Kröger11, F Lanza12, J Marsh13, M Mohty14, A Sureda15, A Velardi16 and A Madrigal17 for the European Society for Blood
and Marrow Transplantation EBMT
In all, 661 of 680 centers in 48 countries reported 37 818 hematopoietic SCT (HSCT) in 33 678 patients (14 165 allogeneic (42%), 19
513 autologous (58%)) in the 2012 survey. Main indications were leukemias, 10 641 (32%; 95% allogeneic); lymphoid neoplasias, 19
336 (57%; 11% allogeneic); solid tumors, 1630 (5%; 3% allogeneic); and nonmalignant disorders, 1953 (6%; 90% allogeneic). There
were more unrelated donors than HLA-identical sibling donors (54% versus 38% (8% being mismatched related donor HSCT)). Cord
blood was almost exclusive in allogeneic transplants (5% of total). Since 2011, the highest increases in allogeneic HSCT were for
AML in CR1 (12%) and for myeloproliferative neoplasm (15%). For autologous HSCT the main increases were for plasma cell
disorders (7%), non-Hodgkin lymphoma (4%) and autoimmune disease (50%). There were 4097 pediatric patients o18 years of age
receiving HSCT, 2902 received an allogeneic and 1195 an autologous HSCT. Overall, 69% of allogeneic and 64% of autologous HSCT
were performed in dedicated pediatric centers and the remainder in combined adult and pediatric centers. Distributions of
diseases, donor types and stem cell source for all patients and pediatric patients in particular are shown. A percentage of centers
fulfilling the annual required criteria for patient numbers for JACIE accreditation are provided.
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INTRODUCTION
Hematopoietic SCT (HSCT) is an established procedure for many
acquired and congenital disorders of the hematopoietic system,
including disorders of the immune system, and as enzyme
replacement in metabolic disorders.1–4 The annual activity survey
of the European Society of Blood and Marrow Transplantation
(EBMT), describing the status of HSCT in Europe and affiliated
countries, has become an instrument that is used to observe
trends and to monitor changes in technology use.5–10 The survey
captures the numbers of HSCT performed in the preceding year
from each participating team, divided by indication, donor type
and stem cell source. The standardized structure of the survey
over many years and the excellent commitment of the participat-
ing teams allow us to observe changes over time and to evaluate
factors associated with these changes. More recently, the survey
has included additional information on novel cell therapies with
hematopoietic stem cells for non-hematopoietic use, as well as on
the use of non-hematopoietic stem and progenitor cells.11 This
coincides with the recent interest of the World Health Organiza-
tion (WHO; www.who.org) in cell and tissue transplants and
further stresses the need for adequate and timely information
(http://www.who.int/topics/transplantation/en/). The analysis of
the survey data spanning over 20 years has shown a continued
and constant increase in the annual numbers of HSCT and
transplant rates (number of HSCT/10 million inhabitants) for both
allogeneic and autologous HSCT.
This report is based on the 2012 survey data. In addition to
transplant rates and indications, stem cell source and donor type
in allogeneic HSCT, the activity for adult and pediatric HSCT is
collected separately.
PATIENTS AND METHODS
Data collection and validation
Participating teams were invited to report data for 2012 by indication, stem
cell source and donor type as listed in Table 1. The survey allows the
reporting of additional information on the numbers of subsequent
transplants performed as a result of relapse, rejection or those that are
part of a planned sequential transplant protocol. Supplementary informa-
tion on the numbers of DLI, reduced-intensity HSCT and the numbers of
pediatric HSCT is also collected. Quality control measures included several
independent systems: confirmation of validity of the entered data by the
reporting team, selective comparison of the survey data with MED-A data
sets in the EBMT Registry database and cross-checking with the National
Registries.
Teams
In all, 680 centers from 48 countries were contacted for the 2012 survey (38
European and 10 affiliated countries), of which 661 teams from 48
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countries (38 European, 10 affiliated countries) reported their numbers.
This corresponds to a 97% return rate and includes 543 active EBMT
member teams. An additional 19 active teams failed to report in 2012 and
6 teams reported no activity due to transplant program development or
closure.
Contacted teams are listed in the online appendix (Supplementary
Information) in alphabetical order by country, city, EBMT center code, with
their reported numbers of first and total HSCT, and of first allogeneic and
autologous HSCTs. The WHO regional office definitions (www.who.org)
were used to classify countries as European or non-European. According
to information received, there were no blood or marrow transplants
performed in Albania, Andorra, Armenia, Georgia, Liechtenstein, Malta,
Moldavia, Monaco, Montenegro and San Marino in 2012. Ten non-
European countries participated in the 2012 EBMT survey: Algeria,
Kazakhstan, Iran, Israel, Jordan, Lebanon, Nigeria, Saudi Arabia, South
Africa and Tunisia. Their data, 6.6% of the total data set, are included in all
analyses.
Definitions
Patient and transplant numbers. Wherever appropriate, patient numbers
corresponding to the number of patients receiving a first transplant and
transplant numbers reflecting the total number of transplants performed
are listed. Multiple transplants may include multiple transplants defined as
subsequent transplants within a planned double or triple autologous
or allogeneic transplant protocol, and retransplants (autologous or
allogeneic) defined as unplanned HSCT for rejection or relapse after a
previous HSCT. New in 2012 is the overview of pediatric HSCT defined as
transplants for patients o18 years of age. All centers performing HSCT on
patients above and below the age of 18 were considered combined adult
and pediatric centers. There were 56 (25 allogeneic and 31 autologous)
patients reported by 21 dedicated pediatric centers who were >18 years of
age at time of transplant. These centers continued to be counted as
dedicated pediatric centers.
As a result of these data, we are now able to calculate the percentages
of centers fulfilling the annual number of transplant requirements for JACIE
accreditation as specified by the Foundation for the Accreditation of
Cell Therapy (FACT)–JACIE standard using the 2012 activity survey data
(http://www.jacie.org/). Although there is no definition of age for pediatric
patients in FACT–JACIE standards, the EBMT pediatric disease working
party (PDWP) defines pediatric patients according to the International
Conference of Harmonization as individuals up to 18 years of age.
Information on stem cell source includes BM, peripheral blood or cord
blood; transplants with more than one source were categorized as cord
blood HSCT if cord blood was present or peripheral blood HSCT if BM and
peripheral blood were used.
Data collection included information on the use of reduced-intensity
conditioning transplants, as defined by EBMT. Information on additional
cellular therapies was subdivided into: HSC for non-hematopoietic use;
non-hematopoietic stem cell therapies; MSC therapies for rejection or
GVHD prevention/treatment; and DLI. Collection of information was
validated by cross-checking with a similar more detailed survey carried
out by TERMIS-EU (Tissue Engineering and Regenerative Medicine
International Society; www.termis.org), EULAR (European League against
Rheumatism; www.eular.org), ICRS-EU (International Cartilage Repair
Society; www.cartilage.org) and ISCT (International Society of Cellular
Therapy; www.celltherapysociety.org).11
Transplant rates
Transplant rates, defined as numbers of HSCT per 10 million inhabitants,
were computed for each country without adjustments for patients
who crossed borders and received their HSCT in a foreign country.
Population numbers were obtained from Eurostats for the European
countries (http://epp.eurostat.ec.europa.eu/portal/page/portal/statistics/
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Participating teams in 2012. Of the 661 teams, 411 (62%)
performed both allogeneic and autologous transplants; 229
(35%) restricted their activity to autologous HSCT only; 15 teams
(2%) to allogeneic transplants only; and 6 teams (1%) reported
having performed no transplants in 2012 because of renovation or
temporary closure of the transplant unit.
Overall, 118 (18%) centers performed transplants on both adult
and pediatric patients; 109 (16%) centers were dedicated pediatric
transplant centers; and 434 (66%) centers performed transplants
on adults only (29 581 transplants; 11 263 allogeneic and 18 318
autologous).
Numbers of patients and transplants
A total of 33 378 patients received their first transplant in 2012. Of
these, 14 165 (42%) were allogeneic and 19 513 (58%) autologous.
Furthermore, there were 2501 retransplants (1098 allogeneic/
1403 autologous) and 1639 multiple transplants (88 allogeneic/
1551 autologous), bringing the total to 37 818 HSCT procedures,
15 351 allogeneic (41%) and 22 467 autologous (59%) procedures
performed in 2012, which is an increase of 6% compared with
2011 and a 30% and 56% increase compared with 2007 and 2002,
respectively.12
Indications for HSCT in 2012 are listed in detail in Table 1. Main
indications were leukemias, 10 641 (32% of total; 95% of which
were allogeneic); lymphoid neoplasias including non-Hodgkin's
lymphoma, Hodgkin lymphoma and plasma cell disorders, 19 336
(57%; 11% allogeneic); solid tumors, 1630 (5%; 3% allogeneic); and
nonmalignant disorders, 1953 (6%; 90% allogeneic). As seen in
previous years, the majority of HSCT for lymphoid malignancies
were autologous, whereas most of the transplants for leukemia
were performed using stem cells from allogeneic donors.
Autologous HSCT for nonmalignant disorders predominantly
includes patients with autoimmune disorders.
Figures 1a and b show transplant rates by country for allogeneic
and autologous HSCT. Median transplant rates per 10 million
inhabitants were 112 (range, 0.1–561) for allogeneic HSCT and 235
(range, 3.4–667) for autologous HSCT.
Distributions of indications for HSCT are shown in Figures 2a
and b for allogeneic and autologous HSCT, respectively.
When compared with 2011 the total number of transplants
increased by 6% (5.5% allogeneic HSCT and 6.4% autologous
HSCT).13 The number of unrelated donor transplants increased by
5.4% from 7799 to 8224. The most significant increases in
allogeneic HSCT were for AML in CR1 (12%) and for myelo-
proliferative neoplasm (15%). For autologous HSCT there was a
decrease in activity for acute leukemia (8% for AML and 22% for
ALL) but an increase for plasma cell disorders by 7% and non-
Hodgkin's lymphoma by 4%. Autologous HSCT for autoimmune
disease had increased by 50%.
Stem cell source and donor type
There were clear differences in the use of stem cell sources
between autologous and allogeneic HSCT. Of the 22 467 auto-
logous transplants, 176 (1%) were BM derived and 22 285 (99%)
were derived from PBSC or from combined peripheral blood and
BM. Only six autologous cord blood HSCT were reported for 2012.
Of the 15 351 allogeneic transplants, 3476 (23%) were BM,
11 117 (72%) were peripheral blood and 758 (5%) were cord blood
transplants. BM remained the preferred source of stem cells for
allogeneic transplants for nonmalignant disorders (62%). Cord
blood was used as stem cell source from unrelated donors in 694
(91%), from HLA-identical siblings in 58 (8%), 6 (0.1%) were from
other family members and 6 were autologous. Overall, the use of
cord blood as a stem cell source was slightly reduced from 833 in
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2011 to 758 in 2012. The highest incidence of cord blood
transplants from unrelated donors was seen in France, Spain, Italy,
the UK and the Netherlands: 511 (74% of all unrelated cord blood
HSCT reported to the EBMT). On the contrary, use of alternative
related donors, mainly haploidentical donors increased by 24%
to 1217.
Donors for the 15 351 allogeneic HSCT were HLA-identical
siblings (5806; 38%), other family members (1217; 8%), syngeneic
twin donors (46; 0.3%), unrelated BM or peripheral blood donors
(7530; 49%) or unrelated cord blood donors (694; 4%). The
percentage of unrelated donor HSCT continues to increase and
has reached 54% of all allogeneic HSCT in 2012.14
Reduced-intensity conditioning
Numbers of reduced-intensity conditioning HSCT continued to
increase from 1436 in 2000 to 5865 in 2012.15 Reduced-intensity
conditioning was used for 38% of all allogeneic HSCT, a proportion
similar to that of the previous year’s survey.
DLI
In 1997, 305 patients were reported as having received DLI after
transplant; this has increased to 2251 in 2012 and corresponds to
15% of patients with an allogeneic HSCT.
Additional cellular therapies
Twenty-one teams from 11 countries reported having treated 189
patients with hematopoietic stem cells for non-hematopoietic use
in 2012. The main indications were cardiovascular, 152 (140
autologous); neurological, 20 (all autologous); tissue repair, 9
(7 autologous) and epithelial, 8 (5 autologous). In addition, 403
patients in 75 teams and 18 countries received mesenchymal
stromal cellsfor prevention/treatment of GVHD (344), prevention/
treatment of graft failure (21) and for unspecified reasons (38).
Numbers of pediatric patients and transplants
New in the 2012 survey is the possibility of reporting the number
of pediatric transplants performed either in dedicated pediatric
transplant centers or in centers performing transplants in both
adult (>18 years of age at transplant) and pediatric patients.
In all, 4041 transplants, 2877 (71%) allogeneic and 1164 (29%)
autologous, were reported in patients under the age of 18 years at
transplant. An additional 56 (25 allogeneic and 31 autologous)
patients >18 years at the time of transplant were reported by 21 of
the dedicated pediatric centers giving a total of 4097 pediatric
transplants (2902 allogeneic and 1195 autologous) in 2012.16 The
proportion of autologous to allogeneic HSCT is different in
pediatrics (29% autologous) compared with adults (62% auto-
logous), and is mainly used for treating solid tumors. The pediatric
population has continued to represent ~ 20% of the entire
population and is somewhat out of proportion to the number of
Allogeneic transplants
per 10 million population
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Figure 1. Transplant rates in Europe (= total number of HSCT per 10
million inhabitants) by participating country. (a) Allogeneic trans-
plant rates/10 million population in 2012. (b) Autologous transplant






































Figure 2. Absolute numbers and relative proportions of indications
for an HSCT in Europe in 2012. (a) Proportions of disease indications
for an allogeneic HSCT in Europe in 2012. (b) Proportions of disease
indications for an autologous HSCT in Europe in 2012.
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adult patients in this population. Also this population, although a
minority, is still a significant minority that includes a number of
unique diagnoses such as the hemoglobinopathies, immune
deficiencies, immune dysregulation and metabolic diseases, all of
which are not common or present at all in the adult HSCT
population.
Donor type was HLA-identical sibling and twin, 1170 (40%);
other family member, 350 (12%); and unrelated, 1382 (48%). Stem
cell sources for allogeneic transplants were BM, 1729 (60%); PBSC,
847 (29%); and cord blood, 326 (11%; 51 targeted sibling, 3 other
family member and 272 unrelated).
Pediatric transplant rates by country for allogeneic and
autologous HSCT are shown in Figures 3a and b. Figure 3c shows
pediatric cord blood transplant rates. Transplant rates for
allogeneic HSCT (>55 per 10 million population) were reported
in Israel, Italy, Saudi Arabia and Slovenia. For autologous HSCT
transplant rates (>45 per 10 million population) were reported in
Israel and Finland.
2760 (67%; 1999 allogeneic and 761 autologous) of the 4097
pediatric patients were performed in dedicated pediatric trans-
plant centers. The remaining 1337 (903 allogeneic and 434
autologous) were performed in centers that performed transplants
in both adults and pediatric patients. Figures 4a and b show the
percentages of pediatric HSCT performed in dedicated pediatric
centers as opposed to combined centers by country for allogeneic
and autologous HSCT, respectively.
Stem cell source does not differ significantly when comparing
pediatric patients transplanted in dedicated pediatric centers (BM
63%, PB 26%, CB 11%) with pediatric patients transplanted in
combined adult and pediatric centers (BM 52%, PB 37% CB 11%).
Donor types are also comparable (HLA-identical sibling 39% vs
Pediatric allogeneic HSCT
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Figure 3. Pediatric transplant rates in Europe (= total number of
HSCT per 10 million inhabitants) by participating country in 2012 in
both center types. (a) Allogeneic transplant rates/10 million
population. (b) Autologous transplant rates/10 million population.
(c) Cord blood HSCT transplant rates/10 million population.
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Figure 4. Absolute numbers and relative proportions of indications
for pediatric HSCT in the 109 dedicated centers in Europe in 2012.
(a) Proportions of pediatric disease indications for an allogeneic
HSCT in Europe in 2012. (b) Proportions of pediatric disease
indications for an autologous HSCT in Europe in 2012.
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44%; unrelated donors 49% vs 45%; other related donors 12%
vs 11%).
Indications for pediatric HSCT are shown in Figures 5a and b
and are limited to data from the 109 dedicated pediatric centers.
The main indication for allogeneic HSCT is ALL (520; 26%), and
primary immune deficiencies (315; 16%). For autologous HSCT,
however, it is solid tumors (504; 66% including 267 (53%)
neuroblastomas) and lymphomas (111; 15%).
The main indication for 354 HSCT performed using haploiden-
tical family donors (12% of all pediatric allogeneic transplants) was
leukemia.
JACIE accreditation criteria
Using the information available from allogeneic and autologous
adult and pediatric centers as well as that reported by combined
centers, we looked at transplant number requirements for JACIE
accreditation and calculated the percentage of centers fulfilling
those requirement criteria on the basis of the reported 2012 data.
Of centers performing allogeneic (and autologous) adult HSCT,
177 of 219 (81%) fulfilled the criterion of 10 allogeneic HSCT in
2012. Of 209 centers performing only autologous adult HSCT, 191
(91%) fulfilled the criterion of five autologous HSCT in 2012. Of 95
dedicated pediatric-only allogeneic centers, 66 (69%) fulfilled the
criterion of 10 allogeneic pediatric HSCT per annum. Of 14
dedicated pediatric autologous only HSCT centers, 6 (43%) fulfilled
the criterion of five pediatric autologous HSCT. Of 118 centers that
reported both adult and pediatric HSCT activity, 85 were
allogeneic (and autologous, as accreditation for allogeneic permits
autologous HSCT as well) adult and pediatric combined centers
and 46 (54%) fulfilled the criterion of at least five adult and five
pediatric allogeneic HSCT in 2012. There were 33 remaining
centers performing adult and pediatric autologous HSCT. Of these,
27 performed adult allogeneic HSCT as well and 22 of the 27 (81%)
fulfilled the criterion of 10 allogeneic HSCT. Six centers performed
only autologous HSCT for adults and children. Of these six centers,
all fulfilled the criterion for adult autologous HSCT. For this specific
combination (adult and pediatric autologous HSCT) JACIE has not
defined a requirement. We did not include the six centers
reporting no transplants in 2012 in this calculation.
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Figure 5. Percentage of types of pediatric transplants performed in the 109 dedicated centers in Europe in 2012. (a) Percentage of pediatric
allogeneic HSCT performed in pediatric-only centers. (b) Percentage of pediatric autologous HSCT performed in pediatric-only centers.
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DISCUSSION
The EBMT activity survey has been conducted annually since 1990.
The 2010 survey reported for the first time >30 000 patients
transplanted in a given year. This trend continues with an
additional increase by 6% in 2012, suggesting that HSCT remains
an increasingly important treatment modality in the era of
targeted antibody and molecular therapy. The present 2012
report is on 37 818 transplants.
HSCT for some indications continues to increase but not for
others. Of interest is the growth of allogeneic HSCT for AML CR1,
myeloproliferative neoplasm, plasma cell disorders and primary
immunodeficiency disorders. For autologous HSCT, autoimmune
diseases saw a significant increase, smaller increases were
observed for myeloma and non-Hodgkin's lymphoma, whereas
AML CR1 decreased by 11%.
We present data on pediatric transplants performed in
dedicated pediatric centers compared with pediatric patients
transplanted in combined adult and pediatric centers. Approxi-
mately twice as many pediatric patients are transplanted in
dedicated pediatric centers when compared with combined
pediatric and adult centers. It would be of interest to compare
outcomes between these groups but these data are not available.
It is also of interest, that more pediatric patients receive BM than
PBSC, irrespective of donor type. This is explained by the higher
incidence of nonmalignant conditions and the higher risk for
chronic GVHD with peripheral blood as a stem cell source. The
percentage of patients transplanted in dedicated pediatric centers
varies considerably by country, probably related to policies in
different countries; it does not appear to be related to the size of
the country.
Lastly, we used the data of the 2012 survey to analyze the
proportion of centers fulfilling quantitative accreditation criteria of
JACIE. A large majority of adult centers do fulfill these criteria;
however, for reasons explained by the lower incidence of pediatric
indications for HSCT, the percentage of centers fulfilling accred-
itation criteria is lower for dedicated pediatric centers but even
lower for centers with combined adult and pediatric HSCT. These
data may serve to advance the discussion of strengthening
pediatric competence as opposed to combining forces between
adult and pediatric specialists and that of the benefit of proximity
for patients as opposed to concentrating competence into fewer
but larger and therefore more geographically distant centers.17,18
Readers should keep in mind that accreditation criteria are not
based on the activity of a single year and therefore the data
presented here should be interpreted acknowledging this fact.
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